DCM
SBBP

Delpha Capital Management’s Strongbridge Biopharma plc. SBBP Stock Holding History

Delpha Capital Management’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-870
Closed -$6K – 1454
2017
Q4 		$6K Buy
+870
New +$5.43K 0.01% 1246

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Delpha Capital Management's SBBP Position: Q1 2018 in Review

Delpha Capital Management sold out of Strongbridge Biopharma plc. (SBBP) in Q1 2018, closing a stake of 870 shares — an estimated $6K sold.

Delpha Capital Management first reported a position in SBBP in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 65 funds tracked by Wall St. Rank hold SBBP as of Q1 2018.

  • Delpha Capital Management reported no remaining Strongbridge Biopharma plc. position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 870 Strongbridge Biopharma plc. shares in Q1 2018, an estimated $6K.
  • Delpha Capital Management first reported a position in Strongbridge Biopharma plc. in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Strongbridge Biopharma plc. position peaked at $6K in Q4 2017.
  • 65 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.